Amgen Inc. $AMGN Stock Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 16.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 675,485 shares of the medical research company’s stock after acquiring an additional 95,436 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Amgen were worth $284,724,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Petredis Investment Advisors LLC raised its stake in Amgen by 2.5% during the third quarter. Petredis Investment Advisors LLC now owns 1,066 shares of the medical research company’s stock worth $449,000 after acquiring an additional 26 shares in the last quarter. Rare Wolf Capital LLC lifted its holdings in shares of Amgen by 12.0% during the third quarter. Rare Wolf Capital LLC now owns 626 shares of the medical research company’s stock valued at $264,000 after acquiring an additional 67 shares during the period. DUTCH ASSET Corp lifted its holdings in shares of Amgen by 14.1% during the third quarter. DUTCH ASSET Corp now owns 2,536 shares of the medical research company’s stock valued at $1,069,000 after acquiring an additional 314 shares during the period. 55 North Private Wealth LLC boosted its stake in shares of Amgen by 19.9% in the 3rd quarter. 55 North Private Wealth LLC now owns 1,147 shares of the medical research company’s stock valued at $483,000 after purchasing an additional 190 shares in the last quarter. Finally, Cypress Capital LLC boosted its stake in shares of Amgen by 1.7% in the 3rd quarter. Cypress Capital LLC now owns 8,251 shares of the medical research company’s stock valued at $3,478,000 after purchasing an additional 139 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. This represents a 23.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen Trading Up 3.3%

Shares of AMGN opened at $438.94 on Wednesday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market cap of $237.30 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 3.11 and a beta of 0.41. The stock has a fifty day moving average price of $416.19 and a two-hundred day moving average price of $376.06. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Tezspire Phase 3 results: Amgen and AstraZeneca reported that Tezspire produced statistically significant and clinically meaningful improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. The data could expand Tezspire’s commercial opportunity beyond severe asthma. Tezspire Phase 3 results
• Positive Sentiment: Upcoming oncology presentation: Amgen will host an investor webcast during the European Society for Medical Oncology Congress on October 24. New cancer-drug data could provide additional visibility into the company’s pipeline and growth prospects. Amgen ESMO 2026 presentation
• Positive Sentiment: Higher analyst valuation: Goldman Sachs raised its price target for AMGN to $481, signaling potential upside from recent trading levels and reinforcing improving sentiment toward the company. Goldman Sachs raises Amgen price target
• Positive Sentiment: Strong financial performance: Amgen recently exceeded consensus estimates for quarterly revenue and earnings per share, with revenue up 9.5% year over year. Investors are increasingly viewing the company’s diversified portfolio as capable of delivering renewed growth.
• Neutral Sentiment: Compared with Bristol Myers Squibb, Amgen offers stronger recent top-line growth, while Bristol Myers has a lower valuation and substantial free cash flow. The comparison highlights AMGN’s growth appeal but also its relatively fuller valuation. Amgen versus Bristol Myers Squibb
• Negative Sentiment: At roughly 27 times earnings, AMGN is not a deep-value healthcare stock, and its high debt-to-equity ratio increases sensitivity to execution and pipeline setbacks. Investors still need evidence that newer products can sustain growth as mature medicines face competition.

Analysts Set New Price Targets

AMGN has been the topic of several analyst reports. Argus upped their target price on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Wells Fargo & Company cut their price target on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a report on Monday, October 12th. TD Cowen lifted their price target on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Guggenheim reduced their price target on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 13th. Finally, Morgan Stanley decreased their price objective on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $387.93.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.